Risk of Bleeding Following NOAC Use in Patients With Acute Ischemic Stroke Treated With Alteplase
This Taiwanese cohort study evaluates the risk of bleeding and mortality after alteplase treatment for patients with acute ischemic stroke treated with non –vitamin K antagonist oral anticoagulants (NOACs) vs not treated with NOACs.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
More News: Activase | Bleeding | Internal Medicine | Ischemic Stroke | Stroke | Study | Taiwan Health | Vitamin K | Vitamins